Not Signed In -
Schizophrenia |
Schizoid personality disorder; Schizotypal personality disorder |
Clinical Trial: Electroconvulsive Therapy in Clozapine Refractory Schizophrenia
This study is currently recruiting patients.
|
Purpose
This study will investigate electroconvulsive therapy (ECT) as an additional treatment for patients who have failed to adequately respond to clozapine.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Schizophrenia | Procedure: ECT Drug: Clozaril | Phase I Phase II |
MedlinePlus related topics: Schizophrenia
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Efficacy Study
Official Title: ECT in Clozapine Refractory Schizophrenia
Further Study Details:
Expected Total Enrollment: 64
Study start: December 2000
ECT augmentation of clozapine will be compared to clozapine monotherapy in schizophrenic patients who continue to have psychotic symptoms despite optimal treatment with clozapine.
Eligibility
Ages Eligible for Study: 18 Years - 60 Years, Genders Eligible for Study: Both
Criteria
Inclusion criteria:
- Receiving at least two 400 mg doses of chlorpromazine equivalents for at least 4 weeks (may include newer antipsychotics)
- Having substantial psychotic symptoms despite at least 12 weeks of treatment (at least 8 weeks at a consistent dose)
Location and Contact Information
Christopher Phillips, RN 718-470-8163 cphillip@lij.edu
New York
Zucker Hillside Hospital, Glen Oaks, New York, 11004, United States; Recruiting
Georgios Petrides, MD 718-470-8569 gpetrides@lij.edu
Christine J Svetina, Ph.D. 718-470-8448 csvetina@lij.edu
Georgios Petrides, MD, Principal Investigator
Chitra Malur, MD, Sub-Investigator
Max Fink, MD, Sub-Investigator
Samuel Bailine, MD, Sub-Investigator
Alan Mendelowitz, MD, Sub-Investigator
Christine Svetina, Ph.D., Sub-Investigator
Jeffrey Gold, MD, Sub-Investigator
John Kane, MD, Sub-Investigator
Nina Schooler, Ph.D., Sub-Investigator
Christine J Svetina, Ph.D. 718-470-8448 csvetina@lij.edu
Georgios Petrides, MD, Principal Investigator
Chitra Malur, MD, Sub-Investigator
Max Fink, MD, Sub-Investigator
Samuel Bailine, MD, Sub-Investigator
Alan Mendelowitz, MD, Sub-Investigator
Christine Svetina, Ph.D., Sub-Investigator
Jeffrey Gold, MD, Sub-Investigator
John Kane, MD, Sub-Investigator
Nina Schooler, Ph.D., Sub-Investigator
More Information
Study ID Numbers: 60390-01A2
Record last reviewed: November 2004
Last Updated: November 18, 2004
Record first received: July 24, 2002
ClinicalTrials.gov Identifier: NCT00042224
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Record last reviewed: November 2004
Last Updated: November 18, 2004
Record first received: July 24, 2002
ClinicalTrials.gov Identifier: NCT00042224
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005
Resources
- Ask NOAH About: Schizoaffective Disorder Fact Sheet (New York Online Access to Health, The New York Hospital Cornell Medical Center (NOAH))
- Ask NOAH About: Schizophrenia Fact Sheet (New York Online Access to Health, The New York Hospital Cornell Medical Center (NOAH))
email this page
print this page
bookmark this page
feedback on this page
